[unknown]

原著和名: [記載なし]科名: オトギリソウ科 = Guttiferae採集地: 長野県 白馬岳 四谷 (信濃 白馬岳 四谷)採集日: 1950/7/26採集者: 萩庭丈壽整理番号: JH038306国立科学博物館整理番号: TNS-VS-98830

Additional file 2: of Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy

Table S2. Demographic characteristics and prevalence (95% CIs) of comorbidities for gout cases and controls, where cases were defined according to the strict definition of requiring ≥ 2 visits with a diagnosis of gout (DOCX 98 kb

Additional file 1: of Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy

Table S1. Definition of comorbidities based on ICD and/or ATC codes (DOCX 94 kb

Additional file 1: Table S1. of Factors associated with initiation and persistence of urate-lowering therapy

Definition of comorbidities by ICD10 codes and ULT by ATC codes. (DOCX 91 kb

Additional file 1: Table S1. of Factors associated with initiation and persistence of urate-lowering therapy

Definition of comorbidities by ICD10 codes and ULT by ATC codes. (DOCX 91 kb

Additional file 3: Table S3. of Factors associated with initiation and persistence of urate-lowering therapy

Distribution of kidney function defined by eGFR and presence of renal disease in incident cases at date of first gout diagnosis and missing. (DOCX 92 kb

Figure 2

<p>A. Balb/C mouse knee joint 30 days following intra-articular transfer of cells overexpressing Flt3-L. Arrows indicate bone erosions. Abbreviations: C = cartilage, M = meniscus, S = synovitis. B. Balb/C mouse knee joint 30 days following intra-articular transfer of cells not overexpressing Flt3-L. Abbreviations: C = cartilage, JC = joint cavity, M = meniscus, ST = synovial tissue.</p

Clinical data regarding 130 RA-patients and 103 controls participating in the study.

*<p>N.A. = not analyzed.</p

Flt3-L levels in synovial fluids and sera of RA patients and of control subjects.

<p>Median displayed in the horizontal line. RA serum (n = 130, median 80, range (min 0–max 3320), RA SF (n = 130, median 160 pg/ml, range (min 20–max 1980), control subjects serum (n = 70, median 70.5 pg/ml, range (min 0–max 160), and control subjects SF (n = 37, median 120 pg/ml, range (min 0–max 360).</p

Percentage of major leukocyte populations in bone marrow and spleen of sunitinib treated mice.

<p>1–3 pooled experiments, 9–19 mice, n.s  =  not significant.</p